Vaccination against hepatitis B: results of the analysis of 2000 population members in Croatia.

D Palmović, J Crnjaković-Palmović
Author Information
  1. D Palmović: University Hospital of Infections Diseases Dr Fran Mihaljević, Zagreb, Croatia.

Abstract

The results of the analysis of vaccination against hepatitis B performed in 2,000 persons of high-risk groups in Croatia are described. All susceptible non-immunocompromised persons (HBsAg, anti-HBs, and anti-HBc negative) received either plasma-derived vaccine (HB-Vax MSD, 20 micrograms per dose) or recombinant HB vaccine (ENGERIX-B, SKB, 20 micrograms per dose) according to a 0.1 and 6-month schedule. Hemodialysis patients received four doses of HB vaccine (40 micrograms per dose). Seroconversion occurred in 98% of health care workers, 98.5% of family members of HBsAg chronic carriers, 98% of infants born to HBsAg carrier-mothers and 92% of hemodialysis patients. The percentage of poor-responders (titer of anti-BHs = 1-10 mIU/ml) for the groups was 2, 2, 8 and 20%, respectively, while low-responders (titer of anti-BHs = 10.1-100 mIU/ml) were 5, 4.5, 12 and 26%, respectively. A significant prevalence of non-responders, poor-responders and low-responders among male health care workers was noticed (p = 0.01, 0.026 and 0.002, respectively). Females significantly prevailed among excellent-responders (p = 0.0039). In hemodialysis patients, there were 8% non-responders, 19.5% poor-responders, and 26% low-responders. A significant difference between the percentage of good-responders (titer of anti-HBs = 101-1,000 mIU/ml) and excellent-responders (titer of anti-HBs over 1,000 mIU/ml) among health care workers and hemodialysis patients was documented (91% versus 46.5%, p < 0.0001). The combined passive-active immunization (hyperimmune hepatitis B globulin + hepatitis B vaccine) was effective in 98% of infants born to HBsAg carrier-mothers, and only one boy developed subclinical HBV infection (HBsAg and anti-HBc positive findings with normal ALT-values).(ABSTRACT TRUNCATED AT 250 WORDS)

References

  1. Infection. 1993 Jan-Feb;21(1):42-5 [PMID: 8449581]
  2. Pathol Biol (Paris). 1991 Sep;39(7):686-91 [PMID: 1758720]
  3. JAMA. 1982 Apr 9;247(14):2012-5 [PMID: 7038174]
  4. Scand J Infect Dis Suppl. 1983;38:13-6 [PMID: 6580721]
  5. Nephron. 1992;61(3):339-40 [PMID: 1386908]
  6. J Med Virol. 1991 Sep;35(1):50-4 [PMID: 1940883]
  7. Lijec Vjesn. 1986 Feb-Mar;108(2-3):95-100 [PMID: 3959743]
  8. Infection. 1982;10(2):55-7 [PMID: 7095862]
  9. Nephron. 1992;61(3):324-5 [PMID: 1386904]
  10. Br Med J (Clin Res Ed). 1983 Apr 23;286(6374):1305-8 [PMID: 6404440]
  11. Postgrad Med J. 1991 Mar;67(785):256-8 [PMID: 1829519]
  12. Semin Liver Dis. 1991 May;11(2):84-92 [PMID: 1832236]
  13. Clin Nephrol. 1992 Jul;38(1):36-43 [PMID: 1499167]
  14. Lancet. 1989 Nov 11;2(8672):1161-2 [PMID: 2572888]
  15. Ital J Gastroenterol. 1990 Aug;22(4):195-7 [PMID: 2131945]
  16. Nephron. 1992;61(3):269-70 [PMID: 1386899]
  17. J Infect. 1987 Nov;15(3):221-4 [PMID: 2961815]
  18. N Engl J Med. 1980 Oct 9;303(15):833-41 [PMID: 6997738]
  19. Nephron. 1992;61(3):278-83 [PMID: 1386900]
  20. J Infect. 1991 Jan;22(1):5-9 [PMID: 1825836]
  21. BMJ. 1991 Feb 9;302(6772):313-6 [PMID: 1825799]
  22. J Exp Med. 1992 Feb 1;175(2):495-502 [PMID: 1531063]
  23. Nephron. 1992;61(3):331-2 [PMID: 1386907]
  24. Lancet. 1983 Dec 10;2(8363):1323-8 [PMID: 6139668]
  25. Gut. 1993;34(2 Suppl):S17-9 [PMID: 8314488]
  26. BMJ. 1991 Jul 13;303(6794):97-101 [PMID: 1830505]

MeSH Term

Adult
Aging
Carrier State
Child
Chronic Disease
Croatia
Female
Health Personnel
Hepatitis B
Hepatitis B Antibodies
Hepatitis B Vaccines
Humans
Immunization Schedule
Immunization, Secondary
Infant
Male
Renal Dialysis
Risk Factors
Sex Characteristics

Chemicals

Hepatitis B Antibodies
Hepatitis B Vaccines

Word Cloud

Created with Highcharts 10.0.00HBsAg=hepatitisvaccinepatientstitermIU/mlB2000anti-HBsmicrogramsperdose98%healthcareworkers5%hemodialysispoor-respondersrespectivelylow-respondersamongpresultsanalysispersonsgroupsCroatiaanti-HBcreceived20HB1membersinfantsborncarrier-motherspercentageanti-BHs526%significantnon-respondersexcellent-respondersvaccinationperformedhigh-riskdescribedsusceptiblenon-immunocompromisednegativeeitherplasma-derivedHB-VaxMSDrecombinantENGERIX-BSKBaccording6-monthscheduleHemodialysisfourdoses40Seroconversionoccurred98familychroniccarriers92%1-10820%101-100412prevalencemalenoticed01026002Femalessignificantlyprevailed00398%19differencegood-responders101-1documented91%versus46<0001combinedpassive-activeimmunizationhyperimmuneglobulin+effectiveoneboydevelopedsubclinicalHBVinfectionpositivefindingsnormalALT-valuesABSTRACTTRUNCATEDAT250WORDSVaccinationB:2000population

Similar Articles

Cited By